PTSD is one of the mental-health conditions people often ask about when researching medical cannabis. That interest is understandable: PTSD can affect sleep, mood, memory, threat response, relationships and daily life. But a PTSD diagnosis does not by itself mean someone may qualify for a medical cannabis prescription.
In the UK, suitability depends on a specialist assessment. The clinician needs to understand the diagnosis, previous treatment history, current symptoms, medicine interactions, substance-use risk, impairment risk and any mental-health factors that could make cannabis-based treatment unsafe or unsuitable.
This guide is for UK patients and carers. It is not medical advice and it does not replace support from a GP, mental-health team, trauma service, psychiatrist or specialist prescriber. If someone feels at risk of harming themselves or others, they need urgent help through NHS urgent mental-health routes, 111, 999 in an emergency, or their local crisis service.
The short answer
Medical cannabis is not a routine first-line PTSD treatment in UK public guidance. NHS and NICE PTSD guidance focuses on trauma-focused psychological therapies, with medicines considered in some situations. NICE guidance on cannabis-based medicinal products does not give a PTSD-specific recommendation.
That does not mean PTSD can never be discussed in a private specialist cannabis assessment. It means the prescriber has to judge the individual case carefully. Some patients may be assessed because previous recommended treatments have not worked well enough, caused problems, or been unsuitable. Others may not be suitable because the risks are too high.
The careful wording is this: medical cannabis may be accessible for suitable patients where a specialist can justify it, but PTSD diagnosis alone is not a prescription route.
For the wider access context, see MCPH guides on medical cannabis qualifying conditions and how the medical cannabis prescription process works in the UK.
How PTSD is usually treated
NHS PTSD information describes symptoms such as reliving events, nightmares, avoidance, being constantly on edge, sleep problems, irritability and changes in mood. NICE PTSD guidance places trauma-focused psychological therapy at the centre of treatment for many patients, including trauma-focused CBT and EMDR where appropriate. Medicines such as antidepressants may be considered in some cases.
That context matters because a cannabis assessment should not erase the usual PTSD care pathway. A prescriber needs to know what has already been tried, what helped, what caused problems, and what remains difficult now. For some patients, the main issue may be nightmares. For others it may be hypervigilance, anxiety, pain, depression, dissociation, sleep disruption, or the side effects of other medicines.
Patients do not need to present a perfect story. They do need to be honest about what has happened and what support they have or have not been able to access.
Why PTSD needs trauma-informed screening
PTSD can sit alongside depression, anxiety, panic, dissociation, substance-use concerns, chronic pain, sleep problems, self-harm risk or suicidal thoughts. Cannabis can also affect mood, perception, anxiety, memory, concentration and impairment. This is why the screening needs to be careful, not just administrative.
A specialist may ask about:
- the PTSD diagnosis and who made it
- trauma-focused therapy, EMDR, counselling or other psychological support already tried
- medicines tried, including antidepressants, sedatives or sleep medicines
- symptoms now, including nightmares, flashbacks, avoidance, hypervigilance, sleep and mood
- current or past self-harm or suicidal thoughts
- psychosis symptoms, bipolar or mania risk, severe depression and dissociation
- alcohol, non-prescribed cannabis, CBD or other substance use
- medicines, supplements and possible interactions
- driving, work, caring responsibilities and safety-sensitive tasks
Good trauma-informed assessment should be clear and respectful. It should not make the patient feel judged. At the same time, a clinician cannot safely prescribe without asking difficult questions where risk is relevant.
Records and previous treatment history
A clinic may ask for a Summary Care Record or relevant GP surgery records to confirm diagnoses, medicines and previous treatments. This is usually an admin records step, not a request for the GP to approve medical cannabis.
For PTSD, records can be more complicated than for some physical conditions. Some therapy history may sit with NHS talking therapy services, community mental-health teams, veterans’ services, private therapists or other providers. If records are incomplete, patients should be honest about that rather than trying to fill gaps with guesses.
The clinician is looking for enough information to make a safe decision. That can include why previous treatment did not work, why it was stopped, whether side effects were a problem, or whether a treatment was unsuitable because of trauma history, access barriers or clinical advice.
Evidence limits and private prescribing nuance
Some patients report that cannabis-based medicines help with sleep, nightmares, anxiety or hyperarousal. Those reports matter as patient experience, but they do not remove the need for careful evidence wording.
Current UK official guidance does not support saying that medical cannabis is a proven PTSD treatment. NICE NG144 does not provide a PTSD recommendation, and NHS medical cannabis guidance keeps routine public prescribing narrow. Specialist private prescribing can be broader where the prescriber can justify an unlicensed cannabis-based medicinal product for an individual patient, but that is still a clinical decision with governance, monitoring and risk controls.
This distinction matters. MCPH should not tell patients that PTSD automatically opens the door. It should also not suggest that PTSD can never be part of a specialist medical cannabis assessment. The honest middle is more useful: PTSD may be discussed, previous treatment history and risk screening matter, and the clinician decides.
Side effects, interactions and impairment
PTSD patients may already be taking antidepressants, sedatives, sleeping tablets, pain medicines or other medicines. CBD and THC can affect how other medicines work, and THC can cause impairment, anxiety, paranoia, confusion, dizziness or changes in perception in some people.
That is why patients should disclose:
- prescribed medicines
- over-the-counter medicines and supplements
- non-prescribed CBD
- non-prescribed cannabis use
- alcohol or other substance use
- previous bad reactions to cannabis or other psychoactive medicines
Driving and work safety need direct discussion. A prescription is not a statement that someone is fit to drive. Patients should not drive while impaired, and they should understand the UK drug-driving law and the prescriber’s advice.
Questions to take to a consultation
Useful questions include:
- Based on my records, do I look like someone who may qualify for assessment?
- Which parts of my PTSD history raise extra caution?
- How do you screen for dissociation, psychosis, severe depression, suicidality and substance-use risk?
- What previous therapies or medicines do you need evidence of?
- How would you monitor nightmares, mood, anxiety, sleep, impairment and side effects?
- What should I do if symptoms worsen after starting treatment?
- How would medical cannabis fit alongside my current PTSD care rather than replacing it?
The purpose is not to demand a particular product. It is to make the assessment safer and more honest.
What this article is not saying
This article is not saying that medical cannabis treats PTSD. It is not saying that PTSD automatically makes someone eligible. It is not recommending CBD, THC, flower, oil, extracts, a clinic, a pharmacy, a route or a dose.
It is saying that PTSD can be part of a specialist assessment for some UK patients, especially where previous treatments have not worked well enough, caused problems, or been unsuitable. Because PTSD is a mental-health condition with serious possible risks, the assessment needs to be source-aware, trauma-informed and clinically cautious.
Sources
- NHS: PTSD
- NICE: Post-traumatic stress disorder, NG116
- NHS: Medical cannabis
- NICE: Cannabis-based medicinal products, NG144
- NHS England: Cannabis-based products for medicinal use
- GMC: Information for doctors on cannabis-based products for medicinal use
- CQC: Cannabis-based medicinal products: what CQC expects from providers
- RCPsych: Cannabis and mental health
- GOV.UK: Drug driving law
